Avid Bioservices, Inc. Logo

Avid Bioservices, Inc.

CDMOP

(1.0)
Stock Price

25,06 USD

-43.08% ROA

-176.54% ROE

-4.57x PER

Market Cap.

660.279.285,00 USD

267.31% DER

0% Yield

-101.07% NPM

Avid Bioservices, Inc. Stock Analysis

Avid Bioservices, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Avid Bioservices, Inc. Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

2 PBV

The stock's PBV ratio (1.83x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 DER

The stock maintains a fair debt to equity ratio (99%), indicating a reasonable balance between the money it owes and the ownership it possesses.

4 ROE

Negative ROE (-1.66%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-0.7%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-1.407) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Avid Bioservices, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Avid Bioservices, Inc. Technical Stock Analysis
# Analysis Recommendation

Avid Bioservices, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Avid Bioservices, Inc. Revenue
Year Revenue Growth
1995 100.000
1996 3.100.000 96.77%
1997 300.000 -933.33%
1998 500.000 40%
1999 100.000 -400%
2000 1.000 -9900%
2001 979.000 99.9%
2002 3.766.000 74%
2003 3.921.000 3.95%
2004 3.314.000 -18.32%
2005 4.959.000 33.17%
2006 3.193.000 -55.31%
2007 3.708.000 13.89%
2008 6.093.000 39.14%
2009 18.151.000 66.43%
2010 27.943.000 35.04%
2011 13.492.000 -107.11%
2012 15.233.000 11.43%
2013 21.683.000 29.75%
2014 22.401.000 3.21%
2015 26.781.000 16.35%
2016 44.686.000 40.07%
2017 57.630.000 22.46%
2018 53.621.000 -7.48%
2019 53.603.000 -0.03%
2020 59.702.000 10.22%
2021 95.868.000 37.72%
2022 119.597.000 19.84%
2023 149.266.000 19.88%
2024 101.580.000 -46.94%
2024 139.911.000 27.4%
2025 160.692.000 12.93%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Avid Bioservices, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1995 0
1996 1.700.000 100%
1997 30.000.000 94.33%
1998 7.600.000 -294.74%
1999 8.800.000 13.64%
2000 8.075.000 -8.98%
2001 7.380.000 -9.42%
2002 13.506.000 45.36%
2003 8.744.000 -54.46%
2004 9.673.000 9.6%
2005 11.164.000 13.36%
2006 12.415.000 10.08%
2007 15.876.000 21.8%
2008 18.279.000 13.15%
2009 18.424.000 0.79%
2010 24.658.000 25.28%
2011 29.462.000 16.31%
2012 35.688.000 17.45%
2013 24.306.000 -46.83%
2014 27.723.000 12.33%
2015 42.996.000 35.52%
2016 59.529.000 27.77%
2017 28.297.000 -110.37%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%
2024 0 0%
2025 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Avid Bioservices, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 700.000
1996 900.000 22.22%
1997 3.300.000 72.73%
1998 4.500.000 26.67%
1999 6.200.000 27.42%
2000 4.236.000 -46.36%
2001 3.812.000 -11.12%
2002 2.478.000 -53.83%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 14.317.000 100%
2021 16.764.000 14.6%
2022 20.626.000 18.72%
2023 27.179.000 24.11%
2024 0 0%
2024 25.196.000 100%
2025 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Avid Bioservices, Inc. EBITDA
Year EBITDA Growth
1995 3.400.000
1996 700.000 -385.71%
1997 -32.700.000 102.14%
1998 -10.900.000 -200%
1999 -18.800.000 42.02%
2000 -9.604.000 -95.75%
2001 -9.792.000 1.92%
2002 -11.794.000 16.97%
2003 -9.289.000 -26.97%
2004 -10.611.000 12.46%
2005 -15.379.000 31%
2006 -19.897.000 22.71%
2007 -21.044.000 5.45%
2008 -23.654.000 11.03%
2009 -15.813.000 -49.59%
2010 -12.497.000 -26.53%
2011 -34.687.000 63.97%
2012 -42.070.000 17.55%
2013 -28.030.000 -50.09%
2014 -34.371.000 18.45%
2015 -49.316.000 30.3%
2016 -54.103.000 8.85%
2017 -28.152.000 -92.18%
2018 -19.278.000 -46.03%
2019 -5.622.000 -242.9%
2020 -10.230.000 45.04%
2021 12.376.000 182.66%
2022 15.341.000 19.33%
2023 4.603.000 -233.28%
2024 -33.192.000 113.87%
2024 -7.569.000 -338.53%
2025 1.472.000 614.2%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Avid Bioservices, Inc. Gross Profit
Year Gross Profit Growth
1995 -900.000
1996 3.100.000 129.03%
1997 600.000 -416.67%
1998 1.200.000 50%
1999 -3.400.000 135.29%
2000 517.000 757.64%
2001 1.391.000 62.83%
2002 3.766.000 63.06%
2003 1.061.000 -254.95%
2004 1.102.000 3.72%
2005 558.000 -97.49%
2006 -104.000 636.54%
2007 412.000 125.24%
2008 1.289.000 68.04%
2009 9.087.000 85.81%
2010 19.227.000 52.74%
2011 6.196.000 -210.31%
2012 5.080.000 -21.97%
2013 9.088.000 44.1%
2014 9.291.000 2.18%
2015 11.188.000 16.96%
2016 21.720.000 48.49%
2017 19.371.000 -12.13%
2018 -2.924.000 762.48%
2019 7.224.000 140.48%
2020 3.932.000 -83.72%
2021 29.307.000 86.58%
2022 36.648.000 20.03%
2023 31.480.000 -16.42%
2024 -18.660.000 268.7%
2024 7.318.001 354.99%
2025 22.852.000 67.98%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Avid Bioservices, Inc. Net Profit
Year Net Profit Growth
1995 -6.900.000
1996 300.000 2400%
1997 -33.200.000 100.9%
1998 -11.800.000 -181.36%
1999 -19.500.000 39.49%
2000 -14.514.000 -34.35%
2001 -9.535.000 -52.22%
2002 -11.718.000 18.63%
2003 -11.559.000 -1.38%
2004 -14.345.000 19.42%
2005 -15.452.000 7.16%
2006 -17.061.000 9.43%
2007 -20.796.000 17.96%
2008 -23.176.000 10.27%
2009 -16.524.000 -40.26%
2010 -14.494.000 -14.01%
2011 -34.151.000 57.56%
2012 -42.119.000 18.92%
2013 -29.780.000 -41.43%
2014 -35.362.000 15.79%
2015 -50.358.000 29.78%
2016 -55.652.000 9.51%
2017 -28.159.000 -97.63%
2018 -21.813.000 -29.09%
2019 -4.215.000 -417.51%
2020 -7.256.000 41.91%
2021 11.212.000 164.72%
2022 127.672.000 91.22%
2023 560.000 -22698.57%
2024 -38.036.000 101.47%
2024 -140.753.000 72.98%
2025 -22.136.000 -535.86%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Avid Bioservices, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 -15
1996 1 0%
1997 -54 100%
1998 -13 -315.38%
1999 -10 -30%
2000 -6 -66.67%
2001 -4 -100%
2002 -4 0%
2003 -3 0%
2004 -4 0%
2005 -4 0%
2006 -4 0%
2007 -4 0%
2008 -4 0%
2009 -3 -50%
2010 -2 0%
2011 -4 33.33%
2012 -4 0%
2013 -2 -200%
2014 -2 0%
2015 -2 0%
2016 -2 0%
2017 -1 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 2 100%
2023 0 0%
2024 -1 0%
2024 -2 100%
2025 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Avid Bioservices, Inc. Free Cashflow
Year Free Cashflow Growth
1995 -1.500.000
1996 -5.500.000 72.73%
1997 -7.700.000 28.57%
1998 -12.800.000 39.84%
1999 -8.400.000 -52.38%
2000 -9.500.000 11.58%
2001 -6.476.000 -46.7%
2002 -13.633.000 52.5%
2003 -10.489.000 -29.97%
2004 -11.662.000 10.06%
2005 -14.258.000 18.21%
2006 -17.575.000 18.87%
2007 -18.699.000 6.01%
2008 -21.618.000 13.5%
2009 -10.156.000 -112.86%
2010 -14.169.000 28.32%
2011 -27.374.000 48.24%
2012 -37.432.000 26.87%
2013 -21.779.000 -71.87%
2014 -29.009.000 24.92%
2015 -45.066.000 35.63%
2016 -48.915.000 7.87%
2017 -41.287.000 -18.48%
2018 -29.785.000 -38.62%
2019 -13.097.000 -127.42%
2020 2.015.000 749.98%
2021 21.318.000 90.55%
2022 -46.946.000 145.41%
2023 -90.525.000 48.14%
2024 -20.853.000 -334.11%
2024 -1.224.000 -1603.68%
2025 -4.991.000 75.48%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Avid Bioservices, Inc. Operating Cashflow
Year Operating Cashflow Growth
1995 -1.500.000
1996 400.000 475%
1997 -4.400.000 109.09%
1998 -9.900.000 55.56%
1999 -7.900.000 -25.32%
2000 -9.299.000 15.04%
2001 -6.234.000 -49.17%
2002 -13.353.000 53.31%
2003 -10.305.000 -29.58%
2004 -11.251.000 8.41%
2005 -13.168.000 14.56%
2006 -16.957.000 22.34%
2007 -18.479.000 8.24%
2008 -20.927.000 11.7%
2009 -10.030.000 -108.64%
2010 -13.865.000 27.66%
2011 -26.462.000 47.6%
2012 -35.878.000 26.24%
2013 -20.926.000 -71.45%
2014 -28.254.000 25.94%
2015 -36.019.000 21.56%
2016 -39.591.000 9.02%
2017 -39.786.000 0.49%
2018 -26.766.000 -48.64%
2019 -11.595.000 -130.84%
2020 5.827.000 298.99%
2021 31.182.000 81.31%
2022 9.465.000 -229.45%
2023 -12.887.000 173.45%
2024 10.952.000 217.67%
2024 6.099.000 -79.57%
2025 -3.680.000 265.73%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Avid Bioservices, Inc. Capital Expenditure
Year Capital Expenditure Growth
1995 0
1996 5.900.000 100%
1997 3.300.000 -78.79%
1998 2.900.000 -13.79%
1999 500.000 -480%
2000 201.000 -148.76%
2001 242.000 16.94%
2002 280.000 13.57%
2003 184.000 -52.17%
2004 411.000 55.23%
2005 1.090.000 62.29%
2006 618.000 -76.38%
2007 220.000 -180.91%
2008 691.000 68.16%
2009 126.000 -448.41%
2010 304.000 58.55%
2011 912.000 66.67%
2012 1.554.000 41.31%
2013 853.000 -82.18%
2014 755.000 -12.98%
2015 9.047.000 91.65%
2016 9.324.000 2.97%
2017 1.501.000 -521.19%
2018 3.019.000 50.28%
2019 1.502.000 -101%
2020 3.812.000 60.6%
2021 9.864.000 61.35%
2022 56.411.000 82.51%
2023 77.638.000 27.34%
2024 31.805.000 -144.11%
2024 7.323.000 -334.32%
2025 1.311.000 -458.58%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Avid Bioservices, Inc. Equity
Year Equity Growth
1995 -600.000
1996 9.000.000 106.67%
1997 14.600.000 38.36%
1998 5.400.000 -170.37%
1999 -2.100.000 357.14%
2000 -2.721.000 22.82%
2001 2.686.000 201.3%
2002 5.083.000 47.16%
2003 2.131.000 -138.53%
2004 14.759.000 85.56%
2005 9.610.000 -53.58%
2006 17.626.000 45.48%
2007 16.989.000 -3.75%
2008 15.595.000 -8.94%
2009 901.000 -1630.85%
2010 13.407.000 93.28%
2011 15.418.000 13.04%
2012 9.483.000 -62.59%
2013 23.760.000 60.09%
2014 67.699.000 64.9%
2015 59.035.000 -14.68%
2016 50.074.000 -17.9%
2017 53.582.000 6.55%
2018 55.738.000 3.87%
2019 53.068.000 -5.03%
2020 41.896.000 -26.67%
2021 77.736.000 46.1%
2022 174.526.000 55.46%
2023 189.470.000 7.89%
2024 183.675.000 -3.16%
2024 60.889.000 -201.66%
2025 58.636.000 -3.84%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Avid Bioservices, Inc. Assets
Year Assets Growth
1995 900.000
1996 10.800.000 91.67%
1997 18.700.000 42.25%
1998 12.000.000 -55.83%
1999 7.400.000 -62.16%
2000 5.953.000 -24.31%
2001 7.900.000 24.65%
2002 7.866.000 -0.43%
2003 5.399.000 -45.69%
2004 19.137.000 71.79%
2005 14.245.000 -34.34%
2006 22.676.000 37.18%
2007 22.997.000 1.4%
2008 23.057.000 0.26%
2009 23.127.000 0.3%
2010 29.335.000 21.16%
2011 34.766.000 15.62%
2012 28.262.000 -23.01%
2013 45.058.000 37.28%
2014 90.545.000 50.24%
2015 97.464.000 7.1%
2016 109.043.000 10.62%
2017 118.112.000 7.68%
2018 95.760.000 -23.34%
2019 78.395.000 -22.15%
2020 107.620.000 27.16%
2021 265.510.000 59.47%
2022 429.843.000 38.23%
2023 451.054.000 4.7%
2024 454.642.000 0.79%
2024 336.557.000 -35.09%
2025 334.642.000 -0.57%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Avid Bioservices, Inc. Liabilities
Year Liabilities Growth
1995 1.500.000
1996 1.800.000 16.67%
1997 4.100.000 56.1%
1998 6.600.000 37.88%
1999 9.500.000 30.53%
2000 8.674.000 -9.52%
2001 5.214.000 -66.36%
2002 2.783.000 -87.35%
2003 3.268.000 14.84%
2004 4.378.000 25.35%
2005 4.635.000 5.54%
2006 5.050.000 8.22%
2007 6.008.000 15.95%
2008 7.462.000 19.49%
2009 22.226.000 66.43%
2010 15.928.000 -39.54%
2011 19.348.000 17.68%
2012 18.779.000 -3.03%
2013 21.298.000 11.83%
2014 22.846.000 6.78%
2015 38.429.000 40.55%
2016 58.969.000 34.83%
2017 64.530.000 8.62%
2018 40.022.000 -61.24%
2019 25.327.000 -58.02%
2020 65.724.000 61.46%
2021 187.774.000 65%
2022 255.317.000 26.45%
2023 261.584.000 2.4%
2024 270.967.000 3.46%
2024 275.668.000 1.71%
2025 276.006.000 0.12%

Avid Bioservices, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.24
Net Income per Share
-2.27
Price to Earning Ratio
-4.57x
Price To Sales Ratio
4.64x
POCF Ratio
89.46
PFCF Ratio
-57.66
Price to Book Ratio
11.23
EV to Sales
5.86
EV Over EBITDA
-112.19
EV to Operating CashFlow
113.31
EV to FreeCashFlow
-72.85
Earnings Yield
-0.22
FreeCashFlow Yield
-0.02
Market Cap
0,66 Bil.
Enterprise Value
0,83 Bil.
Graham Number
6.85
Graham NetNet
-3.12

Income Statement Metrics

Net Income per Share
-2.27
Income Quality
-0.05
ROE
-1.19
Return On Assets
-0.47
Return On Capital Employed
-0.08
Net Income per EBT
4.32
EBT Per Ebit
1.73
Ebit per Revenue
-0.14
Effective Tax Rate
-3.32

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.07
Gross Profit Margin
0.08
Operating Profit Margin
-0.14
Pretax Profit Margin
-0.23
Net Profit Margin
-1.01

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.12
Free CashFlow per Share
-0.18
Capex to Operating CashFlow
2.56
Capex to Revenue
0.13
Capex to Depreciation
1.64
Return on Invested Capital
-0.43
Return on Tangible Assets
-0.43
Days Sales Outstanding
90.18
Days Payables Outstanding
54.71
Days of Inventory on Hand
79.87
Receivables Turnover
4.05
Payables Turnover
6.67
Inventory Turnover
4.57
Capex per Share
0.3

Balance Sheet

Cash per Share
0,58
Book Value per Share
0,92
Tangible Book Value per Share
0.92
Shareholders Equity per Share
0.92
Interest Debt per Share
2.56
Debt to Equity
2.67
Debt to Assets
0.47
Net Debt to EBITDA
-23.4
Current Ratio
1.46
Tangible Asset Value
0,06 Bil.
Net Current Asset Value
-0,17 Bil.
Invested Capital
258896000
Working Capital
0,03 Bil.
Intangibles to Total Assets
0
Average Receivables
0,03 Bil.
Average Payables
0,02 Bil.
Average Inventory
29785500
Debt to Market Cap
0.24

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Avid Bioservices, Inc. Dividends
Year Dividends Growth
2014 2
2015 3 0%
2016 3 0%
2017 3 0%
2018 3 0%
2019 3 0%
2020 3 0%
2021 1 0%

Avid Bioservices, Inc. Profile

About Avid Bioservices, Inc.

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

CEO
Mr. Richard B. Hancock
Employee
222
Address
2642 Michelle Drive
Tustin, 92780

Avid Bioservices, Inc. Executives & BODs

Avid Bioservices, Inc. Executives & BODs
# Name Age

Avid Bioservices, Inc. Competitors